"Sculptra before and after" is the most searched question about this injectable, around 36,000 US searches a month (clickstream estimate, October 2026), ahead of what it is or what it costs. The answer people are looking for is a picture. This page does not show one. It reports what happened when the trial behind Sculptra's 2023 approval put its own before-and-after photographs in front of a reviewer who did not know which was which, and how that compares with the other ways the same faces were rated, read from the trial's posted results on 27 October 2026. What Sculptra is and its approval history are on our Sculptra explainer; how long the result holds is on how long Sculptra lasts; results people regret, and lumps, are on Sculptra side effects.
The trial that measured photographs
The cheek-wrinkle trial (NCT04124692, sponsor Galderma, 149 enrolled, completed August 2021, published as Fabi et al. 2024) randomized adults with moderate or severe cheek wrinkles 2:1 to Sculptra or to no treatment. The treated group had up to four sessions a month apart (150 mg of poly-L-lactic acid reconstituted in 8 mL, with 1 mL of lidocaine, per the publication) and were followed to month 12. Its design matters for everything below: the control group had no injection, so participants and the treating investigators knew who was treated. The registry lists only the outcomes assessor as masked; in practice two raters were blinded: an evaluator who graded cheeks in person, and an independent reviewer who looked at photographs.
What the blinded photograph reviewer saw
The photographic test is the closest thing in the record to a fair before-and-after. For each participant the reviewer was shown the baseline and month-12 photographs as a pair in random order and asked which one was post-treatment. A participant counted as improved when the reviewer picked the month-12 picture. If the photographs carried no information, a reviewer would pick it about half the time.
| Month 12, photographs | Sculptra (n = 84) | No treatment (n = 44) |
|---|---|---|
| Left cheek: month-12 photo picked as "after" | 53.6% | 29.5% |
| Right cheek: month-12 photo picked as "after" | 57.1% | 34.1% |
Read plainly, for treated faces the reviewer did only a little better than a coin toss at telling the after picture from the before. For untreated faces the reviewer picked the month-12 picture less often than chance, which shows the pairs were not neutral either: a year of time, lighting or ageing changed the untreated photographs in a direction the reviewer read as "before". The gap between the two groups, about 23 to 24 percentage points on each cheek, is the trial's photographic signal of a treatment effect. It is a real difference between groups. It is much smaller than the gallery images that dominate this search would suggest.
The same faces, rated four ways
The trial asked four kinds of rater about the same people at month 12. The result depends heavily on who is asked:
| Month 12 | Who rated | Blinded? | Sculptra | No treatment |
|---|---|---|---|---|
| Pairs of photographs, month-12 picked as "after" (mean of two cheeks) | Independent photographic reviewer | Yes | 55.4% | 31.8% |
| ≥1-grade improvement on the cheek-wrinkle scale, at rest | Evaluator, in person | Yes | 71.6% | 26.1% |
| "Improved" or better on the global aesthetic scale | Investigator | No | 94.3% | 4.3% |
| "Improved" or better on the global aesthetic scale | Participant | No | 92.0% | 6.5% |
The first row is our average of the two posted cheek figures; the other rows are as posted. Denominators: 84–88 treated, 44–46 controls.
The two unblinded rows describe how participants and injectors felt about the result, which matters, but people who know they were treated, and have invested time and discomfort in it, rate themselves differently from people who know they were not treated. The blinded rows are the ones that measure the face. The pattern, largest effect where nobody is blinded and smallest where a reviewer sees only photographs, is common in aesthetic trials and is the main reason this site reports the blinded figures first.
By month: when the change appeared
The blinded in-person evaluator graded cheeks at rest at three visits after treatment:
| Visit | Sculptra | No treatment |
|---|---|---|
| Month 7 | 66.2% | 38.6% |
| Month 9 | 70.6% | 31.1% |
| Month 12 | 71.6% | 26.1% |
Two things in that table are easy to miss. The trial took no effectiveness reading before month 7, so it cannot say when in the first half-year the change appeared; swelling just after an injection is not a result and was not counted. And more than a third of untreated people were rated improved at month 7 on a scale graded by eye, which is the size of the background movement any single before-and-after pair has to be judged against. The dynamic version of the same scale, graded while people moved their faces, gave 70.5% against 28.3% at month 12.
The older nasolabial-fold trial that supported the 2009 approval compared Sculptra with collagen rather than with no treatment and followed people to 25 months; its year-by-year figures, and the five-year study, are on how long Sculptra lasts.
Why clinic galleries are not evidence
A gallery picture can be genuine and still tell a reader almost nothing about what to expect:
- Selection. A gallery shows the cases its publisher chose; it records nothing about how many patients were treated or how many were not shown. The trial's 84 photographed treated faces are the whole group, not a selection.
- Conditions. Lighting, camera distance, head angle, expression and make-up change how wrinkles photograph. The trial standardised photographs and still found the untreated pairs shifting by year.
- Timing. A picture taken within days carries swelling from the injection; one taken at a year shows what persisted. Galleries rarely state which.
- Volume and sessions. The trial used up to four vials a month apart. A single picture does not say how much product or how many sessions produced it, which is also what drives the cost.
For the same reasons this site does not publish before-and-after images of any injectable, and its illustrations never show patients.
Safety, in the same trial
The posted safety table records serious adverse events of any cause in 3 of 97 treated participants and 0 of 52 controls; the publication reports no serious event related to the injections. Non-serious events in the treated group were mostly at the injection site. Lumps and nodules, the complication most associated with poly-L-lactic acid, are counted across trials and FDA's device reports on Sculptra side effects, and the separate question of Sculptra against hyaluronic-acid filler has its own page.
What the record does and does not show
It shows that, in one sponsor-run trial of adults with moderate or severe cheek wrinkles, a blinded in-person evaluator rated about seven in ten treated people improved at a year against about a quarter of untreated people, and that a blinded photographic reviewer could pick the treated face's after picture only a little more often than chance. It does not show what any one person's face will look like, it does not compare Sculptra with a sham injection, and it says nothing about areas outside the face. Whether to have the treatment is a conversation for a qualified injector.
Sources
Opened 27 October 2026: ClinicalTrials.gov API, NCT04124692 (protocol, all posted outcome measures including the Independent Photographic Reviewer's assessment and its definition, and the adverse-event module); PubMed abstract of PMID 38206151 (Fabi et al., Journal of Drugs in Dermatology, 2024). Approval history and the 2009 nasolabial-fold trial as recorded on this site's Sculptra explainer (read 30 September 2026). Search volume: DataForSEO clickstream-normalised estimate, United States, measured 26 October 2026. Corrections go to the contact page.